Dynavax Technologies Corporation
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Dynavax Technologies Corporation |
Stock Symbol : | NASDAQ: DVAX |
Class Period Start: | 03/10/2014 |
Class Period End: | 11/11/2016 |
Lead Plaintiff motion: | 01/17/2017 |
Date Filed: | 11/18/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Northern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the January 17, 2017 lead plaintiff deadline in a class action lawsuit filed against Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax” or “the Company”). The suit is pending in the U.S. District Court for the Northern District of California and investors, who purchased Dynavax Technologies Corporation securities between March 10, 2014 and November 11, 2016, have until January 17, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Dynavax Technologies Corporation securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the phase 3 HBV-23 trial for the Company's lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration's concerns and issues, as indicated in a 2013 Complete Response Letter; Dynavax failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; and Dynavax's resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own. On November 14, 2016, the Company revealed that it received a Complete Response Letter from the U.S. Food and Drug Administration requesting additional information on the Company's HEPLISAV-B product in connection with its Biologics License Application. Following this news, NASDAQ: DVAX fell $7.50, or 64.65%, to close at $4.10 on November 14, 2016. If you were negatively impacted by your investment in Dynavax Technologies Corporation securities between March 10, 2014 and November 11, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |